Clinical experience of MEK inhibitors in cancer therapy.
about
Nanoparticle-based targeted therapeutics in head-and-neck cancerPhase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersKB-Rank: efficient protein structure and functional annotation identification via text queryInhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinibA mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaFrom basic research to clinical development of MEK1/2 inhibitors for cancer therapy.High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivoMEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivoPhase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphomaPIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signalingRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.An Encapsulation of Gene Signatures for Hepatocellular Carcinoma, MicroRNA-132 Predicted Target Genes and the Corresponding OverlapsIntegrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway InhibitorsAntitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.Transforming Growth Factor β1-induced Apoptosis in Podocytes via the Extracellular Signal-regulated Kinase-Mammalian Target of Rapamycin Complex 1-NADPH Oxidase 4 AxisPPARgamma and MEK Interactions in CancerOvercoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesCInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade.Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutationsDeciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer.Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.Current and emerging molecular targets in glioma.KRAS and BRAF: drug targets and predictive biomarkers.Mucin as a therapeutic target in pseudomyxoma peritonei.
P2860
Q26999699-06B408A4-1954-4332-AAF3-8433F447EDB6Q27851426-C3922E3A-FE05-44A5-BA85-FBD37EFF1015Q28728482-2DD4143B-8AEF-45B5-872E-E3D772519CE5Q30422319-BB1392BA-914A-4BE9-93BA-88FE5D6D663DQ30498959-AC9B33A9-FC9B-4609-B804-BD2E280603F3Q33426534-4324BB40-0317-4771-BC01-1DD7D121F19FQ33698374-38CD8ED0-A157-4643-8A6E-6C8B4FDF70C8Q33717222-46B04C27-1FA1-4E5D-A586-5080F8929D21Q33945972-6E277EE6-4521-41E7-BB4E-5F088BE9F1FFQ34109756-F1B8DBDF-87A6-49CE-93BA-C16DFE0922ECQ34633455-BF134895-4965-4249-99B8-AB8E2532C22DQ35140947-C227459D-11C3-4444-A1AE-A6725C1C6A38Q35227481-21A298B0-4725-4589-A706-31DC198C94CFQ35679353-FF67CA68-8AD8-4E59-81D7-F27DF26D4F9CQ35692123-D2A3FF66-F6B3-4FAF-9514-C11201FBBEE5Q35891699-F09EF569-AB24-4D9F-A25C-FB512B132832Q35894374-78F14D61-232B-4840-9038-A602E4388A9EQ35970072-89686662-2960-4361-8374-9AA2F6B153BBQ36083385-B5E995E6-A088-4F9C-AB60-D6E430449AF5Q36088484-0B1DB96E-8EB7-43BA-878E-644FBBD45BFFQ36192675-71A59E8C-6918-463E-A703-7CA2579AFA54Q36257295-14BFAFF2-027D-4EC7-9412-E3C64E9F3B1EQ36351612-E8925F99-9C2C-4AFF-9FD1-566D763E8035Q36387871-A9A582B9-BAEB-48BA-A4CD-02CEFDD8B6EFQ36407247-C7F3D799-F446-471E-B756-DADE562A8747Q36737285-CDDBF5AE-005C-43DC-871C-BF4782C313B8Q36812355-920BCDE5-5E0A-4A8B-BA6E-7DF9493231D1Q36813976-B2D70A3A-9381-4045-B9C9-D7D013556B5FQ36973814-41F39A0B-625A-4D70-AEDD-9FF1C15E7749Q37247071-ABC96578-C622-4FA7-A9C2-0B45428736ACQ37269341-CC6E3F5E-8EDD-424B-8C27-C7610E3079D2Q37306997-E42025CE-BA97-416F-A879-B17E5A2959ABQ37339265-12EDD7BC-883D-47EE-9B67-6136EF365030Q37536906-D6030E8B-6054-4420-B41E-839E6843A9DFQ37596249-95743F09-5AB6-4EDD-A234-B8E36F941418Q37661108-212E4518-8929-464C-AE12-20683E85C150Q37753517-99CC85F0-478F-4158-8CCF-FB3329BA6515Q37809861-391CA797-87B0-4B60-BA04-B10C23AEA547Q37815135-5527D89A-5F78-4FD8-B453-7E2A21097361Q38010127-78D62E20-D6D1-446C-B45B-DF3FEE5D2978
P2860
Clinical experience of MEK inhibitors in cancer therapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Clinical experience of MEK inhibitors in cancer therapy.
@ast
Clinical experience of MEK inhibitors in cancer therapy.
@en
Clinical experience of MEK inhibitors in cancer therapy.
@nl
type
label
Clinical experience of MEK inhibitors in cancer therapy.
@ast
Clinical experience of MEK inhibitors in cancer therapy.
@en
Clinical experience of MEK inhibitors in cancer therapy.
@nl
prefLabel
Clinical experience of MEK inhibitors in cancer therapy.
@ast
Clinical experience of MEK inhibitors in cancer therapy.
@en
Clinical experience of MEK inhibitors in cancer therapy.
@nl
P2093
P1476
Clinical experience of MEK inhibitors in cancer therapy.
@en
P2093
James D Winkler
Patricia M LoRusso
Scott A Boerner
P304
P356
10.1016/J.BBAMCR.2006.11.009
P407
P577
2006-11-16T00:00:00Z